REMEVi in the news.

REMEVi Health launched nationwide today, delivering GLP-1 weight-loss care and provider-prescribed peptide and hormone therapies to English- and Spanish-speaking patients across all 50 states and Washington, D.C. Built to operate fully in two languages from the ground up, REMEVi delivers every step of care — from the medical intake form to provider consultations to medication instructions — equally in English and Spanish.

A gap in U.S. healthcare

The United States is home to more than 62 million Hispanic and Latino residents, and roughly 42 million people speak Spanish at home — the largest non-English language group in the country, according to the U.S. Census Bureau. Yet most major telehealth platforms were built in English and, at best, partially translated into Spanish afterward. Research on U.S. hospitals has found that patients with limited English proficiency experience adverse events more often than English-proficient patients, and that those events are more likely to result in physical harm. Language barriers in healthcare are not an inconvenience — they are a measurable patient-safety problem.

Built by founders who lived the problem

REMEVi was co-founded by Blake Chapman and Danai Del Carmen Chapman, a husband-and-wife team who experienced the gap firsthand. Danai, a native Spanish speaker, went through her own weight-management treatment as a patient and found that the medication itself was rarely the hardest part — making sense of appointments, instructions, and decisions about her own body in a second language was.

"I was making decisions about my own health while still translating English in my head. Medicine should not require translation. We built REMEVi so that no patient has to choose between getting care and fully understanding it."

— Danai Del Carmen Chapman, Co-founder, REMEVi

Bilingual at every touchpoint

Unlike platforms that rely on automatic translation, REMEVi was designed bilingual at every touchpoint. Its intake system, patient portal, clinical summaries, medication instructions, and care-coordinator support were all built in English and Spanish at the same time. Every patient case is reviewed by a board-certified, state-licensed provider — a physician (MD) or nurse practitioner — and bilingual care coordinators respond to patients within a two-hour window.

Responsible care, verified

REMEVi is LegitScript-certified (validation ID 50384507) and HIPAA-compliant. Every prescription is reviewed and approved by a licensed provider authorized to practice in the patient's state — REMEVi does not use AI to make prescribing decisions. Compounded medications dispensed through the platform are prepared by state-licensed compounding pharmacies meeting 503A or 503B standards. Compounded medications are not FDA-approved drug products. Patients can cancel, pause, or change their treatment at any time, with no cancellation fees and no minimum commitment.

About REMEVi → How it works → Transparent pricing →

About REMEVi. REMEVi is the first fully bilingual GLP-1 telehealth platform in the United States, delivering weight-loss care, hormone health, and physician-prescribed wellness therapies equally in English and Spanish. Founded in 2026 by Blake Chapman and Danai Del Carmen Chapman and operated by REMEVi LLC in Las Vegas, Nevada, the platform is LegitScript-certified, HIPAA-compliant, and available to patients in all 50 states and Washington, D.C. Every prescription is reviewed by a board-certified, state-licensed provider, and bilingual care coordinators support patients within a two-hour response window.